RxDoctor Payments Data

Jasvindar Singh, MD

Interventional Cardiology · Saint Louis, MONPI 1811931264

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Philips North America LLC accounts for 64.2% of it on its own, with 33 other manufacturers making up the rest. Among interventional cardiology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$695,852in general payments, 2019–2025

Across 1,853 payments — averaging $375.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$447K
  • Shockwave Medical, Inc$67K
  • Biotronik Inc.$34K
  • Boston Scientific$30K
  • Penumbra, Inc.$23K
  • Medtronic$23K
  • plus $71K from 28 others
$297,127in research payments, 2019–2025

Across 147 payments — averaging $2021.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$122K
  • Cardiovascular Systems Inc.$103K
  • Abbott$46K
  • Penumbra, Inc.$26K

What the payments were for

  • Consulting fees$118,61217%
  • Speaking & faculty fees$313,10745%
  • Grants$7,5001%
  • Travel & lodging$135,57819%
  • Food & beverage$116,26917%
  • Education$4,7851%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$695,852 in reported general payments places this provider in the 95th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$80,799
Medicare patients
124
Services billed
411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium14$170
ClopidogrelClopidogrel Bisulfate27$151
Metoprolol Succinate22$147
Ezetimibe11$146
Rosuvastatin Calcium19$110
Nitroglycerin15$90
Amlodipine Besylate12$77
Lisinopril20$36

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →